Dihydropyridine or DHP is arterial-specific vasodilators of peripheral resistance arteries that causes generalized vasodilation, including the intestinal, renal, cerebral, and coronary vascular beds. It is often called calcium-channel agonists and calcium-channel activators. It is particularly well known in pharmacology as L-type calcium channel blockers, which is used in the treatment of hypertension. It has high vascular selectivity thus it is primarily employed to control the vascular resistance and arterial pressure. It includes various drugs such as Cilnidipine, Amlodipine (Norvasc), Felodipine (Plendil), Verapamil (Calan, Isoptin, Covera, Verelan), Nicardipine (Cardene), Nisoldipine, Diltiazem (Cardizem, Tiazac, Dilacor), Isradipine, Nifedipine (Procardia, Adalat) and others. All these drugs are very easy to identify as its drug names end with ‘pine’. These drugs cause noteworthy dilation of blood vessels & relatively little effect on the heart muscle or heart rate. They are most beneficial for treating hypertension. Amlodipine drug holds major share in market owing to rise in preference by the physician or consultant towards amlodipine over the other drugs. Common side effects of dihydropyridine group of calcium channel blockers include dizziness, flushing, headache, and foot & ankle swelling. The most common side effect of both diltiazem and verapamil is constipation, which can occur in up to 25 percentage of people treated with these drugs.
According to study, “Global Dihydropyridine Market Status (2015-2019) and Forecast (2020-2024) by Region, Product Type & End-Use” the key companies operating in the global dihydropyridine market are Shenzhen Simeiquan Biotechnology Co. Ltd., Weifang Union Biochemistry Co., Ltd., Boc Sciences, Yuyao Tuqiang Chemical Co., Ltd., Angene International Limited, Skyrun Industrial Co., Ltd., Triveni Chemicals, Haihang Industry Co., Ltd., Neostar United Industrial Co., Ltd.
Based on type, dihydropyridine market is segmented into purity 98%, purity 99% and other. Based on distribution channel, market is segmented into retail pharmacies, hospitals and others. Based on treatment, market is segmented into hypertension, anti-obesity, angina pectoris, pregnancy, and others. Hypertension often referred as an elevated blood pressure, which is one of the major causes associated with heart diseases. In addition, based on application, market is segmented into veterinary drugs, pharmaceutical and others.
The dihydropyridine market is driven by growth in expansion of the pharmaceutical industry, followed by easy availability of drugs at low cost and increase in research & development (R&D) activities related to cardiovascular diseases. However, side-effects associated with dihydropyridine such as headache etc. may impact the market. Moreover, rise in percentage of the obese population is a key opportunity for market.
Based on geography, the North-American region dominates the dihydropyridine market owing to rise in concern over diseases related to obesity and increase in the geriatric population in the region. Whereas, the European and Asian-Pacific regions are expected to exhibit substantial growth rate due to change in lifestyle and rise in obesity among the young population leads to hypertension or anxiety disorders over the forecast period. In upcoming years, it is predicted that future of the market will be bright on account of growth in demand from pharmaceutical industry during the forecast period.
For More Information, refer to below link:-
Related Report:-
Contact Us:-
Ken Research
Ankur Gupta, Head Marketing & Communications
Ankur@kenresearch.com
+91-9015378249
